The #1 Prescribed biologic* By Allergists and ENTs3
>1 MILLION PATIENTS ON THERAPY ACROSS APPROVED INDICATIONS WORLDWIDE1,4,a
* monoclonal antibody
aThis worldwide number is largely comprised from 10 countries (Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, the UK, and the US), with the rest of the world comprising ≈10% of this number. This number is comprised of the following US approved indications: AD, asthma, CRSwNP, PN, and EoE. Data through August 2024.1,4
WITH DUPIXENT, AIM TO BREAK THE
CYCLE OF RECURRENCE IN CRSwNP1,2:
SOURCES OF
TYPE 2 INFLAMMATION
- DUPIXENT targets IL‑4 and
IL‑13 signaling, two of the key drivers of type 2 inflammation and its disease burdens1,5,6,b
bThe mechanism of dupilumab action has not been definitively established.1
SYMPTOMS
- Rapid results at Day 3 for Loss of Smellc and Day 2 for nasal congestion7,d
Post hoc analysis. Results are descriptive. Definitive conclusions cannot be made.7,8
- Sustained results through
Week 521,2,e-h
Data in adults.1,2,7,9
CONTROL
- 83% fewer patients required surgery1
- 74% fewer patients required systemic steroids1
76% fewer patients required surgery and/or systemic steroids.1,i Individually, these were not multiplicity-adjusted endpoints.1,2 Data in adults.1
Phase 3 Clinical Trials in Adults: Coprimary Endpoints, LSM difference, DUPIXENT 300 mg
Q2W + INCS vs placebo + INCS at Week 241,2
SINUS-24 (DUPIXENT n=143, placebo n=133): NC score: -0.89 (95% CI: -1.07, -0.71).
NPS: -2.06 (95% CI: -2.43, -1.69).
SINUS-52 (DUPIXENT n=295, placebo n=153): NC score: -0.87 (95% CI: -1.03, -0.71).
NPS: -1.80 (95% CI: -2.10, -1.51).
cLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.12, -0.02). Patient-reported outcome.7-9
dLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.13, -0.01).7,9
eLoS at Week 24 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.98 (95% CI: -1.15, -0.81) (P<0.0001).2
fNC at Week 24 in SINUS-52 (coprimary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.87 (95% CI: -1.03, -0.71) (P<0.0001).1,2
gLoS at Week 52 in SINUS-52 (other secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -1.10 (95% CI: -1.31, -0.89).1,2
hNC at Week 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -0.98 (95% CI: -1.17, -0.79) (P<0.0001).2
iIn SINUS-24 and SINUS-52, DUPIXENT (Day 0: n=438; Week 24: n=376; Week 52: n=100); placebo (Day 0: n=286; Week 24: n=187; Week 52: n=61).1
Loss of Smell (LoS) score (range 0-3): reduced score indicates improvement.1
Nasal congestion/obstruction (NC) score (range 0-3): reduced score indicates improvement.1
Nasal polyp score (NPS) (range 0-4 for each nostril, range 0-8 in total): reduced score indicates improvement.1
EoE, eosinophilic esophagitis; INCS, intranasal corticosteroid; LSM, least squares mean; MOA, mechanism of action; PN, prurigo nodularis; Q2W, once every 2 weeks.
Use of DUPIXENT for the CRSwNP indication in patients aged 12-17 years is supported by evidence from studies of DUPIXENT as add-on maintenance treatment in adults with inadequately controlled CRSwNP.1
Patient portrayal.
Multiple Administration
Options
Offer your adult and pediatric patients 12 years and older flexible administration: at home or in office1
Safety
Data
View safety data across clinical trials
Support can make all the difference. DUPIXENT MyWay® is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.
Check Formulary Status in Your Area
See the coverage status for DUPIXENT, prior authorization, and step edit information by ZIP code.
Contact a Field Representative
Connect with a DUPIXENT Field Representative to get answers to your product-related questions.